NCT03311412: Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

NCT03311412
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known, untreated CNS or leptomeningeal metastases that require treatment, or symptoms that suggest CNS involvement- see trial for details
https://ClinicalTrials.gov/show/NCT03311412

Comments are closed.

Up ↑